Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Ivercar-Tuc
 
NCT04701710
RCTivermectincontrolCOVID-19 prophylaxis (excluding children)high
117/117 suggested
  • suggested 87 % decrease in new illness compatible with Covid-19 (PE) but with a low degree of certainty due to high risk of bias
NCT04422561 (Shouman)
 
NCT04422561
RCTivermectinstandard of careCOVID-19 prophylaxis (excluding children)high
228/112 suggested
  • suggested 94 % decrease in new illness compatible with Covid-19 (PE) but with a low degree of certainty due to high risk of bias
results from clinicaltrial.gov
1 study excluded by filtering options (0 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).